| | | PUBLICATIONS (Ranked by impact factor of the journal) |
let-7 Enhances Osteogenesis and Bone Formation while Repressing Adipogenesis of Human Stromal/Mesenchymal Stem Cells by Regulating HMGA2
Using gain- and loss-of-function approaches, scientists demonstrated that let-7 markedly promotes osteogenesis and suppresses adipogenesis of mesenchymal stem cells in vitro. Moreover, let-7 could promote ectopic bone formation of mesenchymal stem cells in vivo. [Stem Cells Dev]
Abstract
Biphasic Nanofibrous Constructs with Seeded Cell Layers for Osteochondral Repair
Primary rat articular chondrocytes and bone marrow-derived mesenchymal stem cells were cultured on the layers of bare poly(lactide-co-caprolactone) (PLCL) and mineralized PLCL nanofibers, respectively, for 7 days, and the biphasic cell-nanofiber construct was investigated at 4 weeks after implantation into nude mice. [Tissue Eng Part C Methods]
Abstract
Effects of Hematopoietic Stem Cell Transplantation on Acyl-CoA Oxidase Deficiency: A Sibling Comparison Study
Researchers describe the natural history of clinical symptoms and brain imaging in two siblings with Acyl-CoA oxidase deficiency, including the younger sibling’s response to allogeneic unrelated donor hematopoietic stem cell transplantation. [J Inherit Metab Dis]
Abstract
CXCR4-Related Increase of Circulating Human Lymphoid Progenitors after Allogeneic Hematopoietic Stem Cell Transplantation
Investigators characterized CD34+Lin–CD10+ lymphoid progenitors in the peripheral blood of allogeneic hematopoietic stem cell transplantation patients. [PLoS One]
Full Article
Human Neural Progenitor Cells Generated from Induced Pluripotent Stem Cells Can Survive, Migrate, and Integrate in the Rodent Spinal Cord
Induced pluripotent stem cell-derived human neural progenitor cells (NPCs) survived grafting into the spinal cord of athymic nude rats with no signs of overgrowth and with a very similar profile to human fetal-derived NPCs. [J Comp Neurol]
Abstract
Human Mesenchymal Stem Cells Alter Macrophage Phenotype and Promote Regeneration via Homing to the Kidney following Ischemia/Reperfusion Injury
Researchers investigated the reparative potential of human bone marrow-derived mesenchymal stem cells and traced their homing patterns following administration to mice with ischemia/reperfusion injury using whole body bioluminescence imaging. [Am J Physiol Renal Physiol]
Abstract
Ex Vivo Bone Morphogenetic Protein 2 Gene Delivery Using Periodontal Ligament Stem Cells for Enhanced Re-Osseointegration in the Regenerative Treatment of Peri-Implantitis
Canine periodontal ligament stem cells were transduced with adenoviral vectors containing bone morphogenetic protein 2 (BMP2/PDLSCs). In vivo, the BMP2/PDLSC group showed significantly more new bone formation and re-osseointegration in peri-implantitis defects compared to the other groups. [J Biomed Mater Res A]
Abstract
Comparison of Cellular Responses of Mesenchymal Stem Cells Derived from Bone Marrow and Synovium on Combined Silk Scaffolds
Scientists investigated and compared the cellular responses of mesenchymal stem cells derived from bone marrow and synovium on combined silk scaffolds that can be used to determine the cell source most appropriate for tissue-engineered ligament. The two cell types were transfected with green fluorescent protein to evaluate their fate after implantation in an intraarticular environment of the knee joint. [J Biomed Mater Res A]
Abstract
Effectiveness of Cationic Liposome-Mediated Local Delivery of Myostatin-Targeting Small Interfering RNA In Vivo
Myostatin-small-interfering RNA (siRNA) and scrambled siRNA-lipoplexes were injected into the masseter muscles of wild type and dystrophin-deficient mdx mice, which model Duchenne muscular dystrophy. [Dev Growth Differ]
Abstract
Isolation of Human Induced Pluripotent Stem Cell-Derived Dopaminergic Progenitors by Cell Sorting for Successful Transplantation
Investigators induced dopaminergic (DA) neurons using scalable culture conditions on human laminin fragment, and the sorted CORIN+ cells expressed the midbrain DA progenitor markers, FOXA2 and LMX1A. When transplanted into 6-OHDA-lesioned rats, the CORIN+ cells survived and differentiated into midbrain DA neurons in vivo, resulting in significant improvement of the motor behavior, without tumor formation [Stem Cell Rep]
Full Article |
Graphical Abstract |
Press Release
|
| |
| REVIEWS |
Lentiviral Vectors for the Treatment of Primary Immunodeficiencies
Scientists describe the recent advancements achieved both in vitro and at preclinical level with lentiviral vectors for the treatment of Wiskott-Aldrich syndrome, chronic granulomatous disease, ADA deficiency, Artemis deficiency, RAG1/2 deficiency, X-linked severe combined immunodeficiency, X-linked lymphoproliferative disease and immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. [J Inherit Metab Dis]
Abstract
Visit our reviews page to see a complete list of reviews in the cell, gene and immunotherapy research field.
![[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.](http://img.en25.com/eloquaimages/clients/StemcellTechnologiesInc/{8c6ba2af-3362-43b6-9324-128647576285}_ON351-AldefluorBasicFACs-645x110.jpg)
|
| | | POLICY |
Confusion as Institute Releases Report on Controversial Acid-Bath Stem-Cell Papers
Beleaguered Japanese researchers are wavering over whether to retract two stunning but controversial papers which detailed a simple acid-bath method of reprogramming mature cells to an embryonic state. At a marathon press conference held in Tokyo, officials from RIKEN, Japan’s largest research institute and home to several of the papers’ authors, announced the findings of an interim investigation into alleged inconsistencies in the studies. [Nature News]
Editorial
Alliance for Regenerative Medicine Announces Introduction of Regenerative Medicine Promotion Act of 2014 in the Senate
The Alliance for Regenerative Medicine announced the introduction of the Regenerative Medicine Promotion Act of 2014 in the U.S. Senate and expressed appreciation for the efforts of its lead sponsors, Senators Barbara Boxer (D-CA) and Mark Kirk (R-IL). [Alliance for Regenerative Medicine]
Press Release
US Senate Approves France Córdova to Lead NSF
The US National Science Foundation (NSF) has a new leader. The US Senate voted to confirm astrophysicist France Córdova to lead the agency, roughly a year after former director Subra Suresh resigned mid-term. [Nature News]
Editorial
Switzerland to Provide Grants while European Funding Is on Hold
The Swiss government is stepping in to support individual researchers currently excluded from receiving grants from the European Union. Hundreds of Switzerland-based scientists who had applied, or intended to apply, for European Research Council grants have been badly hit by the fallout of a referendum last month which obliges the Swiss government to restrict immigration into the country. [Nature News]
Editorial
|
| | | BUSINESS |
Advaxis and UC San Francisco to Evaluate Cancer Immunotherapy Constructs in Prostate Cancer
Advaxis, Inc. announced that it has signed an agreement with the University of California, San Francisco, under which Lawrence Fong, M.D. will evaluate several new immunotherapy constructs, in addition to ADXS-PSA, each built on the Advaxis proprietary technology. [Advaxis, Inc.]
Press Release
Takeda and UCL to Work Together to Tackle Muscle Disorders
Takeda will work with University College London (UCL) to drive research into tackling muscle disorders, in particular muscular dystrophy. The research is being supported through funding of $250,000 from the company’s New Frontier Sciences group. [University College London]
Press Release
TESARO and AnaptysBio Announce Collaboration and Exclusive Worldwide License Agreement for Multiple Immuno-Oncology Programs
TESARO, Inc. and AnaptysBio, Inc. announced an exclusive, worldwide license agreement and immuno-oncology antibody collaboration. Under the terms of the agreement, TESARO receives rights to monospecific antibody drug candidates targeting TIM-3, LAG-3 and PD-1 and dual reactive antibody drug candidates targeting PD-1/TIM-3 and PD-1/LAG-3. [TESARO, Inc.]
Press Release
ReNeuron to Receive Support from Foundation Fighting Blindness for Its Retinal Stem Cell Therapy Candidate for Treatment of Retinitis Pigmentosa
ReNeuron Group plc announced that its ReN003 retinal stem cell therapy candidate for retinitis pigmentosa is to receive support from the US-based Foundation Fighting Blindness, the world’s leading private source for inherited retinal disease research funding. [ReNeuron Group plc]
Press Release
AIM Receives $1 Million Gift to Advance Stem Cell Research
Inaugurating a new era of philanthropic giving for stem cell research in Alabama, the Alabama Institute of Medicine (AIM) announced the generous donation of $1 Million dollars from an anonymous Birmingham resident. [Alabama Institute of Medicine]
Press Release
STEMSOFT Announces Release of New BMT Clinic Software Solution
STEMSOFT™ Software Inc. announced the release of a new BMT cellular therapy transplant software solution, STEMSOFT CLINIC. This new system efficiently manages all patient and donor information in one location complete with an available BMT registry submission and retrieval process for all available forms using the CIBMTR AGNIS system. [STEMSOFT™ Software Inc.]
Press Release
NeoStem Reports Fourth Data Safety Monitoring Board Review of PreSERVE AMI Trial
NeoStem, Inc. announced that the Data Safety Monitoring Board recommended continuing the PreSERVE acute myocardial infarction (AMI) Phase II clinical trial following a fourth interim data and safety review [NeoStem, Inc.]
Press Release
Stem Cell Therapy May Help Severe Congestive Heart Failure
A multi-site study is being conducted, in which stem cells are removed from the bone marrow, their numbers significantly increased by technology developed by Aastrom Biosciences, then injected into multiple weak points in the heart. [Medical College of Georgia at Georgia Regents University]
Press Release
NW Bio Announces Two German Approvals: “Hospital Exemption” for Early Access Program with DCVax-L and Eligibility of DCVax-L for Reimbursement
Northwest Biotherapeutics (NW Bio), a company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has received approval from the Paul Ehrlich Institute (the FDA of Germany) of a “Hospital Exemption” early access program under Section 4b of the German Drug Law. [Northwest Biotherapeutics, Inc.]
Press Release
NeoStem’s Subsidiary, Progenitor Cell Therapy (PCT), Announces Bi-Coastal Facility Expansions
NeoStem, Inc. and its subsidiary, PCT announced that PCT has expanded both its Allendale, NJ and Mountain View, CA current Good Manufacturing Practice facilities to significantly increase its engineering and process development laboratories, and controlled environment space available for client needs. [NeoStem, Inc.]
Press Release
|
|
